PLX — PROTALIX BIOTHERAPEUTICS INC (Healthcare >> Biotechnology)
PLX FAQ
What is PLX's P/E ratio?
PROTALIX BIOTHERAPEUTICS INC (PLX) currently trades at a P/E ratio of 7.58.
What is PLX's ROE?
PROTALIX BIOTHERAPEUTICS INC reports a Return on Equity (ROE) of 22.81%.
What is PLX's dividend yield?
PROTALIX BIOTHERAPEUTICS INC offers a dividend yield of 0.00%.
What is PLX's Deepscope Quality Score?
Deepscope rates PLX's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PLX?
Deepscope's AI Timing Score for PLX is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PLX belong to?
PROTALIX BIOTHERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 2.01
Price
0.05
(2.55%)
Day Change
|
|
|---|
PLX, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
50% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.01 |
| PBV / Sector |
2.35 / 4.58
|
| Earning Per Share | 0.20 |
| PE / Sector |
7.58 / 17.10
GREAT
|
| PEG or PE/Growth / Sector |
-0.04 / 0.52
|
| Average 1M Daily Value |
1.64 M
GREAT
|
| Average 1W Daily Value |
1.25 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
62% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:33 |
| Symbol | PLX |
| Name | PROTALIX BIOTHERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 80.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 157.92 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2 University Plaza, Hackensack, NJ, United States, 07601
Phone: 201 696 9345
Website: https://www.protalix.com
Employees: 226
Sector: Healthcare >> Biotechnology
Description: Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google